{
  "id": "multiple-myeloma-by-payer",
  "display_name": "Multiple Myeloma by Payer",
  "cohort": "Multiple Myeloma, RRMM, by Payer Regimen Coverage (2024–2025)",
  "insight_type": "Payer Coverage Analysis",
  "summary": "Significant variation in use of high-margin regimens based on payer. Medicare patients receive Dara-based regimens 52% of the time vs. only 18% for Commercial Payer B.",
  "chart": {
    "type": "bar",
    "unit": "payer",
    "data": [
      { "name": "Medicare", "value": 52, "gap": 18, "highlight": false },
      { "name": "Commercial A", "value": 41, "gap": 7, "highlight": false },
      { "name": "Medicaid", "value": 29, "gap": -5, "highlight": false },
      { "name": "Commercial B", "value": 18, "gap": -16, "highlight": true },
      { "name": "Commercial C", "value": 22, "gap": -12, "highlight": true },
      { "name": "Self-Pay", "value": 15, "gap": -19, "highlight": true }
    ],
    "benchmark": 34,
    "nccn_target": 40
  },
  "financial_impact": {
    "annual_opportunity": "$325,000/year",
    "math": "$325,000/year = 15% utilization gap × 35 patients × $62,000 adjusted margin difference"
  },
  "clinical_impact": {
    "description": "Addressing payer-specific barriers could improve access to optimal regimens for all patients.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+18.4 months",
        "description": "Potential PFS improvement with optimized regimen selection"
      },
      {
        "type": "Equity",
        "value": "+62%",
        "description": "Improvement in treatment equity across payer types"
      },
      {
        "type": "Auth",
        "value": "-72%",
        "description": "Reduction in authorization denials with proactive approach"
      },
      {
        "type": "OOP",
        "value": "-45%",
        "description": "Reduction in patient out-of-pocket costs with financial counseling"
      },
      {
        "type": "TTT",
        "value": "-9.4 days",
        "description": "Reduced time to treatment initiation"
      }
    ],
    "quantitative": "+18.4 months PFS"
  },
  "peer_comparison": {
    "description": "Top RRMM practices achieve 38%+ Dara-based regimen utilization for Commercial B patients vs. your 18%. Successful practices employ dedicated prior authorization specialists.",
    "peer_benchmark": 38,
    "financial_impact": {
      "annual_opportunity": "$415,000/year",
      "math": "$415,000/year = 20% increase × 35 patients × $59,000 margin difference"
    },
    "action_steps": [
      {
        "text": "Create payer-specific prior authorization protocols",
        "icon": "document"
      },
      {
        "text": "Implement financial navigation program for self-pay patients",
        "icon": "users"
      },
      {
        "text": "Develop payer contract negotiation strategy",
        "icon": "chart"
      },
      {
        "text": "Establish dedicated prior authorization team",
        "icon": "clipboard"
      }
    ]
  },
  "weighted_score": 92,
  "action_steps": [
    {
      "text": "Analyze Commercial B and C authorization requirements",
      "icon": "chart-line"
    },
    {
      "text": "Implement patient assistance program enrollment process",
      "icon": "users"
    },
    {
      "text": "Develop payer-specific authorization documentation templates",
      "icon": "document"
    },
    {
      "text": "Create appeals process for regimen denials",
      "icon": "clipboard"
    }
  ],
  "suggestions": [
    {
      "text": "Negotiate improved regimen coverage with Commercial B and C",
      "icon": "document"
    },
    {
      "text": "Share successful authorization strategies across team",
      "icon": "users"
    }
  ],
  "drilldowns": [
    {
      "label": "View by Provider",
      "cohort": "Multiple Myeloma Regimen Selection by Provider",
      "jsonFile": "multiple-myeloma-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Sites",
      "cohort": "Multiple Myeloma Regimen Selection by Site",
      "jsonFile": "multiple-myeloma-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "Analyze Margins",
      "cohort": "Multiple Myeloma Regimen Margin Analysis",
      "jsonFile": "multiple-myeloma-regimen-margins.json",
      "drilldownLevel": 1
    }
  ]
} 